Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma

Molecular Cancer Therapeutics

Volumn 4, Issue 9, 2005, Pages 1430-1438

  Ho, Joanna W Y ^a   Man, Kwan ^a   Sun, Chris K ^a   Lee, Terence K ^a   Poon, Ronnie T P ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; IMMUNOMODULATING AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; INJURY; LIVER TUMOR; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; G1 PHASE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; PROPYLENE GLYCOLS; SPHINGOSINE; TRANSPLANTATION, HETEROLOGOUS; UMBILICAL VEINS; WOUNDS AND INJURIES;

EID: 33644697587     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0021     Document Type: Article

References (33)

1. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-22.
2. Fiorentino M, Altimari A, Ravaioli M, et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004; 10: 1789-95.
3. Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002;20:1775-85.
4. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001;233:227-35.
5. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994;47:208-15.
6. Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001; 72:764-9.
7. Azuma H, Horie S, Muto S, et al. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res 2003;23:3183-93.
8. Kimura T, Hasegawa T, Nakai H, et al. FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells. Transplantation 2003;75:1469-74.
9. Azuma H, Takahara S, Ichimaru N, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002;62:1410-9.
10. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003;169:2372-7.
11. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138:1303-12.
12. Permpongkosol S, Wang JD, Takahara S, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002;98:167-72.
13. Nagahara Y, Matsuoka Y, Saito K, Ikekita M, Higuchi S, Shinomiya T. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn J Cancer Res 2001; 92:680-7.
14. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1 -phosphate receptors. J Biol Chem 2002; 277:21453-7.
15. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296:346-9.
16. Spiegel S. Sphingosine 1-phosphate: a ligand forthe EDG-1 family of G-protein-coupled receptors. Ann N Y Acad Sci 2000;905:54-60.
17. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397-407.
18. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003;278: 47281-90.
19. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999;99:301-12.
20. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-63.
21. Brown JJ, Parashar B, Moshage H, et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 2000;31:173-81.
22. Lee TK, Man K, Ho JW, et al. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004;25:2397-405.
23. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-82.
24. Uyama O, Okamura N, Yanase M, Narita M, Kawabata K, Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J Cereb Blood Flow Metab 1988;8:282-4.
25. Rossner W, Tempel K. [Quantitative determination of the permeability of the so-called blood-brain barrier of Evans blue (T 1824)]. Med Pharmacol Exp Int J Exp Med 1966;14:169-82.
26. Clasen RA, Pandolfi S, Hass GM. Vital staining, serum albumin and the blood-brain barrier. J Neuropathol Exp Neurol 1970;29:266-84.
27. Rawson RA. The binding of T-1824 and structurally related diazo dyes by the plasma proteins. Am J Physiol 1943;138:708-17.
28. Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg 2003;238:9-28.
29. Herlyn M. Endothelial cells as targets for tumor therapy. J Immunother 1999;22:185.
30. Hobson B, Denekamp J. Endothelial proliferation in turmours and normal tissues: continuous labelling studies. Br J Cancer 1984;49:405-13.
31. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305-26.
32. Ferguson R. FTY720 immunomodulation: optimism for improved transplant regimens. Transplant Proc 2004;36:549-53S.
33. Zhao Y, Man K, Lo CM, et al. Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway. Am J Transplant 2004;4:1399-407.